Hear from an APDS expert.

Learn about Joenja® the first and only FDA approved treatment for APDS that works on the source of the disease itself, not just the symptoms.

Joenja helps restore immune balance by correcting the underlying immune defect in APDS.

See Important Safety Information below.


JOENJA® (leniolisib) is a kinase inhibitor for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Important Safety Information

Verify pregnancy status in female of reproductive potential prior to initiating treatment with JOENJA.

JOENJA may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose of JOENJA.

Live, attenuated vaccinations may be less effective if administered during JOENJA treatment.

Use of JOENJA in patients with modetate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.

The most common adverse reactions (incidence > 10%) seen in clinical trials were headache, sinusitis, and atopic dermatitis.

Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 amd 1500 cells/miroL. No patients developed an ANC <500 cells/microL and there were no reports of infection associated with neutropenia.

Before prescribing JOENJA, please read the full Prescribing Information.